

**ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN PHARMACEUTICAL
ANALYSIS****B. Satya Prasad^{1*}, J. N. Suresh Kumar², P. Pavani³, B. Bhargavi⁴, S. K. Akram⁵, D. Sasi Kumar⁶, K. Vineela Eswari Devi⁷**

India.

***Corresponding Author: B. Satya Prasad**India. DOI: <https://doi.org/10.5281/zenodo.23801316>**How to cite this Article:** B. Satya Prasad^{1*}, J. N. Suresh Kumar², P. Pavani³, B. Bhargavi⁴, S. K. Akram⁵, D. Sasi Kumar⁶, K. Vineela Eswari Devi⁷. (2026). Artificial Intelligence And Machine Learning In Pharmaceutical Analysis. European Journal of Pharmaceutical and Medical Research, 13(11), 173–180.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 01/10/2026

Article Revised on 21/10/2026

Article Published on 01/11/2026

ABSTRACT

Artificial Intelligence (AI) & Machine Learning (ML) are two terms that transformed pharmaceutical sciences, including drug discovery, drug development, precision medicine and nanomedicine. Traditional drug discovery is a long, expensive and failure-prone process that may take over 10 years and million of dollars before it produces a therapeutically active compound ready for clinical trials and commercialization. AI-driven computational approaches can tackle numerous challenges of drug discovery and development, including target or lead identification and optimization, virtual screening, predicting drug target interactions, toxicity and personalized treatment options. The concept of artificial intelligence was first introduced in the 1940s when Alan Turing laid the foundations for machine intelligence theory claiming that there is no fundamental difference between human and machine computation (Turing, 1950). The formal idea of artificial intelligence was further proposed by Mc Carthy, Minsky, Rochester and Shannon who proposed the Dartmouth Hypothesis about the possibility for machines to stimulate human intelligence (Mc Carthy et al 1955). In the following decades the concepts machine learning and deep learning were introduced Schmidhuber in 2015. There are three review papers that discuss the role of AI&ML in pharmaceutical sciences and health care. The first study focus on the role of artificial intelligence in drug discovery and discovery and precision nanomedicine (Zhu et al, 2022). Zhu et al. highlight importance of algorithms and nano-enabled therapeutics for precision nanomedicine. The main ideas of the study include finding and selecting the target developing the optimal drug using nano-enabled therapeutics and individualizing treatment based on patients characteristics. The second review paper discuss the role of AI in spatial structure of protein predicting and drug synergism prediction targeting molecular mechanism and protein drug interactions (Lie et al, 2022). The study by Lei et al. high-light the importance of AI in analyzing and prediction the spatial structure of protein to reveal molecular mechanisms and biological functions. The third review paper was discusses the concept of artificial intelligence, machine learning and deep learning elucidates ethical and social implications and high light the public awarness about AI (Garcia & Salichos, 2022). The study by Garcia & Salichosis a detailed analysis about the opportunities and limitations of AI.I would like to address the main ideas of all three reviewed papers and discuss hoe AL&ML can be applied to various stages of drug discovery and development. I will also comment on such terms as machine learning, deep learning, protein spatial structure prediction, virtual screening precision, precision medicine, nanomedicine, drug synergism prediction, explainable AI.

KEYWORDS: Artificial Intelligence; Machine Learning; Deep Learning; Drug Discovery; Pharmaceutical Analysis; Precision Medicine; Nanomedicine; Drug Target Interactions; Drug Synergism; Protein Structure Prediction; Explainable AI.

1. INTRODUCTION

AI is one of the most promising and revolutionary fields that transformed healthcare and pharmaceutical sciences. AI is a collective name for various form of machine intelligence that can perform task in a way that illustrate

human cognitive functions, ranging from simple calculations to complex learning and decision making abilities. Alan Turing work on machine intelligence laid the foundation for understanding how AI can simulate human intelligence (Turing, 1950).

The Dartmouth Conference of 1956 brought together scientist who formalized the idea of artificial intelligence, while the 1980s and 1990s produced the concept of machine learning (McCarthy et. al., 1955). Currently, AI systems are capable of performing a wide range of tasks, including recognizing speech patterns and visual information, recommending movies or songs, detecting diseases, and creating new medicine. However it is important to highlight the current limitations of AI-driven computer programs.

Drug development is a complex, time consuming and expensive process that involves countless failed attempts before successful drug candidates are identified and prepared for clinical trials. Modern strategies and techniques of drug discovery and development can benefit from AI & ML in many ways. For example, AI-driven in-silico studies can help researchers find potential targets and lead molecules, optimize the most promising candidates predict how a prospective drug will behave and function in the body, determine its pharmacological properties, and identify the best treatment for an individual patient.

The exponential growth of computational biology and related fields, including bioinformatics ,genomics, proteomics, transcriptomics, metabolomics, and structural biology, led to an explosion of biological and chemical data. ML algorithms offer multiple advantages for handling and analyzing big data sets and identifying meaningful patterns that correlate different variables in novel ways. Modern deep learning is capable of capturing associations across many dimension which is particularly important for analyzing biological data.

The article by LeCun et al. discusses the opportunities and limitations of deep learning and reveals why this field has revolutionized AI-driven pharmaceutical sciences and healthcare (LeCun et al. 2015). According to LeCun et al. deep learning enables computers to learn visual pattern, auditory patterns, language based pattern and other types of multidimensional information.^[5-8]

2. Evolution of Artificial Intelligence in Pharmaceutical Sciences

The emergence of artificial intelligence occurred in the middle of the 20th century. Early forms of AI were based on rule-driven algorithms that could solve specific tasks. The Dartmouth Conference of 1956 produced the Dartmouth Hypothesis about the opportunity for machines to simulate human intelligence (McCarthy et al., 1955). However, the early forms of artificial intelligence were limited to individual rule-driven tasks.

Modern AI systems are powered by statistical machine learning algorithms that enable computers to detect patterns within large sets of data. The development of artificial neural networks and access to powerful computer processors enabled the creation of deep learning algorithms that Well-established method. AI can

be integrated into all stages and aspects of target information and validation to improve the efficiency and accuracy of this stage in drug discovery. For instance, AI can process and analyse genomic, transcriptomic, proteomic, metabolomic, and clinical data it identifies potential associations between disease and bio logical targets.^[5,13,14]

3.2 Virtual Screening

In pharmaceutical research, machine learning is regraded as one of the cutting-edge tools able to main valuable patterns in a large st of chemical and bio logical data. AI and ML algorithms can be applied to prioritize the most promising compounds based on their molecular structure, target affinity, pharmaceutical properties and predicted toxicity. the approaches can dramatically reduce the number of compounds that needed to be synthesized and texted experimentally during the drug discovery process.^[11-18]

3.3 Drug Target Interaction

Prediction of drug-target interactions is an integral part of structure-based virtual screening method. computational method of drug -targeted interaction prediction can benefit significantly from the use of AI and ML algorithms. various aspects of drug-target interactions can be predicted computationally, including the binding site, binding efficacy, binding mode or conformation and pharmacological properties of the interaction. in practice, deep learning algorithms can apply successfully to determine how small molecules can bind to a particular target. using AL algorithms, researches can examine thousands of molecular descriptors and pattern that characterize the chemical and structural properties of test compounds.^[12-18, 42]

3.4 Lead Optimization

Lead optimise is the process of improving the qualities of a hit compounds to produce a lead molecule with desirable medical properties. At this stage, researchers optimise the selected compounds so that it has optimal absorption, distribution and metabolism, elimination, selectivity, potency, stability solubility, and other properties. AI can accelerate and improve the hit-to-lead process by predicting how a modification to a lead compound's molecular structure will impact its pharmacological properties.^[13-18]

4. Machine Learning in Drug Discovery

In pharmaceutical research, machine learning is regraded as one of the cutting-edge tools able to main valuable pattern in a large set of chemical and biological data.

4.1 Supervised Learning

Supervised learning algo Rithuns enable finding associations between input and out put variables which can be applied for drug- target interaction prediction, ADME, toxicity, disease class or bio maker identification.

Among the most commonly applied algorithms are random forest, support vector machine, decision tree, logistic regression, gradient boosting.^[21-28]

4.2 Unsupervised Learnin

Unsupervised learning algorithms allow extracting meanings full pattern from an unordered set of data. The main applications include patients stratification, clustering of molecular target or compounds, biomarker identification, gene expression analysis.^[21,22,50]

4.3 Reinforcement Learning

This type of machine learning employs the system of rewards and penalties in order to enable an agent to maximise gains. Reinforcement learning is considered as a promising apporacj for molecule design, synthesis planning and lead optimise.^[25]

5. Deep Learning in Pharmaceutical Research

Deep learning is one of the youngest branches of machine learning involving architectures with multiple films to represent data.

5.1 Artificial Neural Network

Simplified representation of their functioning is based on the use of artificial neurons that mimic the activity of biological neurons, enable to recognise complex pattern and associations. The applications area includes QSAR, drug- target interactions, toxicity productions, and pharmacokinetics.

5.2 Convolutional Neutral Networks

Convolutional neutral networks are known for their ability to capture spatial pattern. The areas of applications include histopathological image analysis medical imaging, cancer screening, computer-aided detection, and molecule encoding.

5.3 Recurrent Neural Networks

Recurrent neutral networks are specifically designed for sequential data analysis. These networks can be used for DNA sequence analysis, protein sequence encoding, clinical reporting mining, and pharmacokinetics.^[28-30]

5.4 Graph Neural Networks

This type of neural network allows encoding complex hierarchical data with nodes and Edes in particular, graphs are extremely useful for representation of molecules with as nodes and bonds as edge graph neural network are currently considered to be one of the most promising approaches for applications on pharmaceutical reach for prediction of molecular properties, drug-target interaction, drug repurposing, and lead optimization.^[31-33]

5.5 Transformer

Transformer are based on the attention mechanism that enables the model to effectively encoded long- range dependencies in both plains text and biological sequences. The applications or this archives in both plains text and biological sequences. The applications f

this architecture includes protein language modelling, protein structure prediction, molecular design, and natural language understanding in bio medical field. Overall advances in deep learning enabled to diversify the areas of applications of AI in pharmaceutical research.^[34,35]

6. AI in Protein Structure Prediction

Protein structure prediction can benefit from AI algorithms that are able to learn the pattern between protein amino acid sequence and its three-dimensional structure.

Protein structure plays a critical role in its interaction with potential ligands and biological functions. I -based approaches can be used for identification of active sites, prediction of protein-ligands interactions, be used for understanding of conformational charges, optimization of molecular docking, increasing of compounds specificity to wards a particular target. Therefore, analysans protein three-dimensional structure using combined experimental and computational approaches can provide critical insights into molecular mechanism of drug action, as well as help identify lead compounds with describable interaction profile.^[9,10,36-42]

7. AI in Precision Medicine

Precision medicine is an emerging field that employs the concept of individual patient profiling in order to understand disease heterogeneity and determine the most optimal therapeutic strategy.

Applications of AI in his field is mainly forced on the analysis of various types of patient data (genomic, molecular, social, clinical) in order to build predictive models that can be used for risk stratifications and identification of optimal treatment options. the area of applications includes disease prediction, precision, diagnostic, individual risk assessment stratification of prediction of adverse drug reactions. he main advantage of using AAI in this field is ability to analyse large amount of multimodal data, which is critical for personalized approaches in oncology, rare disease, and chronic conductions.^[43-45]

8. AI in Precision Nanomedicine

Nanomedicine represents the convergence nanotechnology and pharmaceutical sciences and is focused on the development of the novel treatment strategies with improves efficacy and safety profiles.

These is a need for precise design of nano partials in terms of compositions, size, and surface, characteristics to maximise therapeutic benefits and minimise adverse effects. AI can benefit the design process by predicting nanoparticles behaviour in vivo, analyser their physiochemical properties, interactions with Different biological barriers, toxicity, and drug release profiles. The areas of applications of AI in precision nano medicine include design of optimal nano carriers,

prediction of toxicity, biodistribution analysis, drug release prediction, optimization of nanoparticles physicochemical properties, and personalized treatment options development. The key challenges of the applications of AI in this area include the availability of high-quality annotated data for model training, inter- and intra-individual variability, complexity of multi model data integration, and regulatory endorsement.^[46,47]

9. Pharmaceutical Analysis/Chemometrics

The review highlights the latest trends in application of AI across multiple domains of pharmaceutical research. All the areas of application include drug discovery, drug design, drug delivery, and drug development. In particular, AI can benefit the analysis of complex data in cheminformatics, such as molecular structure encoding, virtual screening, QSAR analysis, molecular dynamics simulations, identification of ADME properties, prediction of toxicity, and drug target interactions analysis. In addition, AI can be employed for analysis of various types of patient data for precision medicine purposes. Finally, nano medicine can benefit from using AI algorithms for nanoparticle design. Through promising, application of AI in pharmaceutical research is limited by the availability of quality data, complexities of data integration, high computational burden.^[48-54]

9.1 Transcription Factors

Transcription factors are regulators of gene expression that can interact with each other and have a synergistic or antagonistic effect on cellular functions. The interplay between transcription factors can be evaluated using AI-assisted approaches to understand their contribution to drug response.

9.2 Signaling Pathways

The interplay between signaling pathways can also be considered. For instance, Akt, Nf-kB, STAT3, ERK, and c-Myc pathways are involved in the development of multidrug resistance.

9.3 Membrane Transport Proteins

Membrane transporters are another class of proteins that can be considered as part of the cellular machinery determining drug response. For instance, p-glycoprotein is a membrane transporter that can actively pump a variety of drugs out of the cell, contributing to multi drug resistance. The contribution of membrane transporters to drug response can also be evaluated using AI-assisted approaches to determine the most promising combination of drugs to overcome resistance.^[55-57]

10. AI in Toxicity Prediction

The safety profile of a pharmaceutical substance is of utmost importance. AI and ML algorithms can be applied to evaluate the toxicity of a drug candidate and predict its potential side effect. The application of AI toxicity prediction can be divided into several areas, including hepatotoxicity prediction, cardiotoxicity prediction, genotoxicity prediction, and general toxicity assessment.

The early prediction of toxicity can help reduce the workload and costs of preclinical and with unacceptable safety profiles.^[5,15,58]

11. AI in Drug Repurposing

AI can be applied to the task of drug repurposing, which involves finding new therapeutic indications for already existing pharmaceutical substances. Drug repurposing is an important area of research because it can significantly reduce the costs and time of drug discovery by building on already known properties of a substance. AI can assist researchers in the task of drug repurposing by mining the relationships between drugs, targets, genes, pathways, diseases, and clinical indications. Thus, AI can help find new connections between diseases and drugs.^[59]

12. Explainable Artificial Intelligence

One of the main challenges of using complex ML algorithms in pharmaceutical research and other sensitive areas is that their inner workings are not fully understood. This limitation is often referred to as the "black-box" nature of such models. Explainable Artificial Intelligence (XAI) refers to methods developed to make ML models more transparent and their decisions more explainable. The ability to interpret the results of ML algorithms is especially important for pharmaceutical research and healthcare in general, as it allows different stakeholders to understand and trust the conclusions made by AI. Thus, XAI is an important area of research that should be further explored to make the most of the opportunities offered by ML algorithms in pharmaceutical research.^[59]

13. Ethical and Regulatory Considerations

The use of AI in pharmaceutical research and healthcare, in general, raises a number of ethical and regulatory concerns. First, the use of patient data for training ML algorithms requires the implementation of appropriate privacy and data security measures. Second, there is a concern regarding the potential for AI to be biased, especially when the training data used to train the algorithms are biased. Third, ethical concerns can arise from the fact that AI can make decisions that are not fully transparent or understood by humans. Fourth, there is a need to ensure that the use of AI in healthcare is fair and does not lead to discriminatory practices. Fifth, the responsibility for the decisions made by AI should be clearly defined. Finally, the use of AI in healthcare requires informed consent from patients.

From a regulatory perspective, the use of AI in pharmaceutical research and healthcare requires appropriate validation and regulatory oversight. Thus, for instance, the FDA requires that AI-based medical devices and pharmaceutical substances are safe, effective, and reliable. In general, the ethical and regulatory considerations regarding the use of AI in pharmaceutical research and healthcare are complex and multifaceted and should be carefully considered before implementing such technologies in practice.^[61,62]

14. Challenges and Limitations

The use of AI in pharmaceutical research and healthcare is not without its challenges and limitations. Some of the main challenges and limitations of using AI in pharmaceutical research include the following.

14.1 Data

AI algorithms require large amounts of data to train on, and the quality of training data has a direct impact on the performance of the algorithm. Thus, the main challenge of using AI in pharmaceutical research is the availability of high-quality training data.

14.2 Data Heterogeneity

The data used to train ML algorithms can come from a variety of sources, including different databases, different laboratories, and different experimental setups. Thus, such data can be highly heterogeneous, which can negatively impact the performance of ML algorithms.

14.3 Black-Box Nature of ML Algorithms

As mentioned above, one of the main challenges of using ML algorithms in pharmaceutical research is their black-box nature.

14.4 Regulatory Hurdles

Another challenge of using AI in pharmaceutical research is that the field of AI-driven pharmaceutical research is highly regulated. Thus, AI-driven pharmaceutical solutions have to go through a lengthy and rigorous validation process before they can be used in practice.

14.5 Economic Considerations

The use of AI in pharmaceutical research is capital-intensive and requires significant investments in computational hardware, software, personnel, data management, and maintenance.

14.6 Reproducibility

A major concern with AI-driven pharmaceutical research is the reproducibility of results. Due to the complexity of ML algorithms, the same results may not be obtained when the same model is applied to different data sets or different computational architectures.^[21,22,48,53,58,59]

15. Future Perspectives

The future of AI in pharmaceutical sciences is very promising, and there are many exciting developments that are expected to take place in the near future. Some of the most exciting opportunities for AI in pharmaceutical sciences include the following

- Integration of multi-omics data
- AI-powered personalized medicine
- Digital twins
- Federated learning
- Quantum computing
- Explainable AI
- AI-powered clinical trials
- AI-enabled nanomedicine

- Automated pharmaceutical manufacturing
- Generative AI

Combining AI with genomics, proteomics, structural biology, nanotechnology, and clinical medicine can support the development of advanced pharmaceutical research platforms that facilitate the discovery and development of new therapeutic approaches at a remarkable pace.

OVERALL COMPARATIVE DISCUSSION

The three articles reviewed above present distinct perspectives on the role of AI in pharmaceutical science. The first examines AI applications in drug discovery and precision nanomedicine, including machine learning, deep learning, predictive modelling, virtual screening, and nanotechnology. The second article explores protein structure, including the use of computational tools to predict three-dimensional protein structures. It also considers drug interactions, transcription factors, signalling pathways, membrane transporters, and molecular mechanisms. Artificial intelligence (AI) and machine learning (ML) are important technologies that are transforming how people live and work. They are widely applied in healthcare, education, business, banking, and the pharmaceutical industry. Although these terms are often used together, they have different meanings and functions.

Artificial intelligence is a broad area of computer science focused on creating systems that can perform tasks commonly associated with human intelligence, such as solving problems, making decisions, understanding language, and recognising images. For example, ChatGPT, virtual assistants, and AI-based medical systems use AI to help people complete tasks more efficiently.

The third article introduces the fundamentals of artificial intelligence and machine learning, their applications across different fields, and their ethical and social implications. Taken together, the three articles suggest that AI and ML can be applied at multiple levels within pharmaceutical science. These technologies can operate at the molecular level, where they can predict protein structures and molecular interactions, and during drug development, where they can optimise virtual screening, simulate drug-target interactions, support lead optimisation, predict toxicity, and identify opportunities for drug repurposing. At the patient level, AI can support precision medicine and nanomedicine. These applications may help tailor approaches to individual patient needs.

AI models are developed by training machine-learning systems to analyse data rather than relying entirely on explicit programming. Four common machine-learning task types include prediction, classification, clustering, and dimensionality reduction.

CONCLUSION

Artificial intelligence is the broader technology that enables machines to perform tasks requiring intelligent behaviour, while machine learning is a branch of AI that allows systems to learn from data. Both technologies can help advance healthcare, pharmacy, scientific research, and everyday life. AI and ML are transformative concepts in the current digital era, supporting progress across pharmaceutical science. From early ideas about machine intelligence to modern deep learning systems, AI innovations have provided pharmaceutical research with useful methods for collecting and analysing large datasets. AI can support many stages of drug discovery and development, including target identification, virtual screening, prediction of drug–target interactions, lead optimisation, and toxicity assessment.

Other applications include drug repurposing, protein-structure prediction, precision medicine, and nanomedicine. The three reviewed articles cover a range of AI applications in pharmaceutical science, from broad overviews to specialised topics. The first article explains how AI can be incorporated into different fields, including pharmaceutical science. The second focuses on methods for studying protein structure and function, while the third provides a general introduction to the subject.

Although AI has demonstrated promise in drug discovery, its use across pharmaceutical science is still developing. Key limitations include the complexity, diversity, and availability of data, as well as challenges involving interpretability, reproducibility, ethics, validation, and implementation. Nevertheless, AI may be integrated into several areas of pharmaceutical science, including multi-omics, structural biology, generative AI, nanomedicine, federated learning, and digital twins. These technologies may help make pharmaceutical research more personalised and precise. AI-supported drug discovery and development is most likely to succeed when combined with traditional research methods and guided by ethical standards and regulations. Overall, AI and ML can contribute to pharmaceutical innovation, support the development of new treatments, and help address patient needs.

REFERENCES

1. Turing AM. Computing machinery and intelligence. *Mind*. 1950; 59(236): 433-460. doi:10.1093/mind/LIX.236.433.
2. McCarthy J, Minsky ML, Rochester N, Shannon CE. A proposal for the Dartmouth summer research project on artificial intelligence. 1955.
3. Schmidhuber J. Deep learning in neural networks: An overview. *Neural Netw*. 2015; 61: 85-117. doi:10.1016/j.neunet.2014.09.003.
4. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature*. 2015; 521(7553): 436-444. Doi: 10.1038/nature14539.
5. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discovery*. 2019; 18(6): 463-477. Doi: 10.1038/s41573-019-0024-5.
6. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discovery Today*. 2019; 24(3): 773-780.
7. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. *Nat Biomed Eng*. 2018; 2(10): 719-731. Doi: 10.1038/s41551-018-0305-z.
8. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat. Med.*, 2019; 25(1): 44-56. Doi: 10.1038/s41591-018-0300-7.
9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with alpha Fold. 2021; 596(7873): 583-589. Doi: 10.1038/s41586-021-03819-2.
10. Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Židek a, et al. Highly accurate protein structure prediction for the human proteome. *Nature*. 2021; 596(7873): 590-596. Doi: 10.1038/s41586-021-03828-1.
11. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. *Curr. Med. Chem.*, 2013; 20(23): 2839-2860.
12. Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. *Pharmacology Rev*.
13. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. *Nat. Mater.*, 2019; 18(5): 435-441. Doi: 10.1038/s41563-019-0338-z.
14. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat. Rev. Drug Discovery*. 2019.
15. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discovery. Today*. 2018; 23(6): 1241-1250. doi:10.1016/j.drudis.2018.01.039.
16. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat. Biotechnol.*, 2019; 37(9): 1038-1040. Doi: 10.1038/s41587019-0224-x.
17. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell*. 2020; 180(4): 688-702.e13. doi:10.1016/j.cell.2020.01.021.
18. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, et al. Rethinking drug design in the artificial intelligence era. *Nat. Rev., Drug Discovery*. 2020; 19(5): 353-364. Doi: 10.1038/s41573-019-0050-3.

19. Lyu J, Irwin JJ. Using machine learning to accelerate virtual screening and drug discovery. *Expert. Opin., Drug Discovery*.
20. Vamathevan J, Spitzer M, Flannick J, Zorn KM, Kellenberger E, et al. Applications of machine learning in drug discovery and development. *Nat. Rev. Drug Discov.*, 2019; 18: 463-477.
21. Bishop CM. *Pattern Recognition and Machine Learning*. New York: Springer; 2006.
22. Hastie T, Tibshirani R, Friedman J. *The Elements of Statistical Learning*. 2nd ed. New York: Springer; 2009.
23. Breiman L. Random forests. *Mach Learn*. 2001; 45: 5-32. Doi:10.1023/a: 1010933404324.
24. Cortes C, Vapnik V. Support-vector networks. *Mach Learn*. 1995; 20: 273-293. Doi:10.1007/BF00994018.
25. Sutton RS, Barto AG. *Reinforcement Learning: An Introduction*. 2nd ed. Cambridge (MA): MIT Press; 2018
26. Vellido A, Lisboa PJG, Vaughan J. Neural networks in business: a survey of Applications (1992-1998). *Expert Syst. Appl.*, 1999; 17(1): 51-70.
27. Goodfellow I, Bengio Y, Courville A. *Deep Learning*. Cambridge (MA): MIT Press; 2016.
28. Lecun Y, Bengio Y, Hinton G. Deep Learning. *Nature*. 2015; 521: 436-444. Doi:10.1038/nature14539.
29. Krizhevsky A, Sutskever I, Hinton GE. Image net classification with deep Convolutional neural networks. *Communes ACM*. 2017; 60(6): 84-90.
30. Hochreiter S, Schmidhuber J. Long short-term memory. *Neural Comput*. 1997; 9(8): 1735-1780.
31. Kipf TN, Welling M. Semi-supervised classification with graph convolutional networks. *ArXiv*. 2017. doi: 10.48550/arXiv.1609.02907.
32. Glimer J, Schoenholz SS, Riley PF, Vinyals O, Dahl GE, Neural message passing for quantum chemistry. *Proc Int Conf Mach Learn*. 2017; 70: 1263-1272.
33. Wu Z, Pan S, Chen F, Long G, Zhang C, Yu PS. A comprehensive survey on graph neural networks. *IEEE Trans Neural Newt Learn Syst.*, 2021; 32(1): 4-24. Doi: 10.1109/TNNLS.
34. Vaswani A, Shazer N, Parmar N, Uszkoreit J, Jones L, Gomes AN, et al. Attention is all you need. *Adv. Neural Inf process Syst.*, 2017; 30: 5998-6008.
35. Delvin J, Chang MW, Lee K, Toutanova K. BERT: pre-training of deep Bidirectional transformers for language understanding. *Proc., NAACL-HLT*. 2019: 4171-4186.
36. Junper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021; 596: 583-589. Doi:10.1038/s41586-021-03819-2.
37. Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W, et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. *science*. 2023; 379(6637): 1123-1130. Doi:10.1126/scienceade2574.
38. Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, et al. Improved protein structure prediction using potentials from deep Learning. *Nature*. 2020; 577(7792): 706-710.
39. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with alpha Fold. *Nature*. 2021; 596: 583-589.
40. Tunyasuvunakool K, Alder J, Wu Z, Green T, Zielinski M, Zidek a, et al. Highly accurate protein structure prediction for the human proteome. *Nature*. 2021; 596: 590-596.
41. Durrant JD, McCammon JA. Molecular dynamics simulations and drug Discovery. *BMC Biol.*, 2011; 9: 71.
42. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. *Molecules*. 2015; 20(7): 13384-13421. Doi:10.3390/molecules200713384.
43. Ashley EA. Towards precision medicine. *Nat Rev Genet*. 2016; 17(9): 507-522. doi:10.1038/nrg.2016.86
44. Collins FS, Varmus H. A new initiative on precision medicine. *N. Engl. J. Med.*, 2015; 372(9): 793-795. Doi:10.1056/NEJMp1500523.
45. Topol EJ. *The Topol Review: preparing the healthcare workforce to deliver the digital future*. London. NHS Health Education England; 2019.
46. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nat. Rev., Drug Discov*. 2021; 20(2): 101-124. Doi:10.1038/s41573-020-0090-8.
47. Balnco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol*. 2015; 33(9): 941-951. doi:10.1038/nbt.3330.
48. Biancolillo A, Marini F. Chemometric methods for spectroscopy-based Pharmaceutical analysis. *Front Chem*. 2018; 6: 576. Doi:10.3389/fchem.2018.00576.
49. Brereton RG. *Chemometrics for pattern Recognition*. Chichester: Wiley; 2009.
50. Wold S, Esbensen K, Geladi P. Principal component analysis. *Chemom Intell. Lab. Syst.*, 1987; 2(1-3): 37-52. Doi: 10.1016/0169-7439(87)80084-9.
51. Rinnan A, Van den Berg F, Engelsen SB. Review of the most common pre-processing techniques for near-infrared spectra. *TrAC Trends Anal Chem*. 2009; 28(10): 1201-1222.
52. Reich G. Near-infrared spectroscopy and imaging: basic principles and pharmaceutical applications. *Adv Drug Deliv. Rev.*, 2005; 57(8): 1109-1143.
53. Sacre PY, Deconinck E, De Beer JO. A survey of chemometric techniques in pharmaceutical analysis. *J Pharm Biomed. Anal.*, 2013; 84: 1-11.
54. El-Gindy A, Hadad GM. Chemometrics in pharmaceutical analysis: an Introduction, review, and future perspectives. *J AOAC Int.*, 2012; 95(3): 609-623. Doi: 10.5740/jaoacinst. SGE_El-Gindy.

55. Nagy B, Galata DL, Farkas A, Nagy ZK. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing-a review. *AAPS J.* 2022; 24: 74. Doi:1208/s12248-022-00706-0.
56. Jain K, Kadam D, Thakur S, Dhole P. Artificial intelligence/machine learning in pharma analysis and quality control: a real-world upgrade. *Indian J Pharm. Educ. Res.*, 2026; 60(2s): S375-S384. doi: 10.5530/ijper.20264489.
57. Gaikwad AS, Pawar SB. Artificial intelligence assisted pharmaceutical analysis for sustainable quality monitoring and continuous manufacturing. *Applications. Discov. ArtifIntell.*, 2026; 6: 820. Doi: 10.1007/s44163-026-01927-4.
58. International council for Harmonization. ICH Q2 (R2): Validation of Analytical procedures. Geneva: ICH; 2023.
59. International Council for Harmonization. ICH Q14: Analytical procedure Development. Geneva: ICH; 2023.